Even at $2M+, ICER calls bluebird's potential gene therapy for blood disorder 'superior' to standard of care
The Institute for Clinical and Economic Review, a drug pricing watchdog, gave a measured thumbs up on Thursday morning to bluebird’s potentially expensive new gene therapy for a rare but debilitating blood disorder, which will go before an FDA advisory committee next Friday.
While bluebird raised some sticker-shock eyebrows with its proposed price of $2.1 million per treatment course of what’s known as beti-cel, ICER said previously in April and again today that the therapy would be cost-effective, as long as there’s an 80% payback option for patients who do not achieve and maintain transfusion independence over a five-year period.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters